CareLit · DOI-Nachweis · Geburtshilfe und Frauenheilkunde
Ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who received no prior therapy for advanced disease
DOI 10.1055/s-0036-1592812
Bibliografische Angaben
Nachweis in CareLit
Autor:innenEM Grischke, A Nusch, N Marschner, W Abenhardt, J Wilke, T Decker, M Just, S Kümmel, C Kurbacher, F Marmé, F Overkamp, F Xuan, M Miller, W Janni
ZeitschriftGeburtshilfe und Frauenheilkunde
Ausgabe10/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Ribociclib, a selective, small-molecule inhibitor of CDK4/6, has exhibited antitumor activity as part of doublet or triplet therapy (ribociclib+ET ± PI3K-inhibitor or everolimus) in estrogen receptor-positive breast cancer models, and in the clinical setting. The phase 3, randomized, double-blind, international, MONALEESA-2 study is evaluating the efficacy and safety of ribociclib + letrozole vs. place…
Zitieren
Zitierempfehlung
EM Grischke, A Nusch, N Marschner, W Abenhardt, J Wilke, T Decker, M Just, S Kümmel, C Kurbacher, F Marmé, F Overkamp, F Xuan, M Miller, W Janni (2016) Ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who received no prior therapy for advanced disease. Geburtshilfe und Frauenheilkunde (10). https://doi.org/10.1055/s-0036-1592812
Mit CareLit weiterarbeiten